Multiple Myeloma, Lymphoma Respond Differently to Treatment for Anemia
A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma.
Health Care Utilization High for Hospitalized Patients With Advanced Cancer
According to a recent study, symptom burden tends to be high among hospitalized patients with advanced cancer, which leads to increased use of health care resources.
Novel EGFR-TKI Superior to Conventional Therapies for NSCLC
The oral, third-generation, irreversible EGFR-TKI osimertinib is superior to standard EGFR-TKIs including gefitinib and erlotinib as a first-line treatment for EGFR mutation-positive advanced NSCLC.
Burden of Sarcoma May Be Underestimated in National Cancer Database
Data from the National Cancer Database, which is heavily dependent on institutional reporting, could be misleading about the burden of sarcomas in the United States.
Novel Adjuvant Therapy Regimen Reduces Relapse in HER2-Positive Breast Cancer
A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer.
NCCN Updates Guidelines for Prevention, Treatment of Cancer-Related Infections
The National Comprehensive Cancer Network recently released updated guidelines for the treatment of cancer-related infections, fever, neutropenia, and other adverse events.
Blue Cross Blue Shield, Google Affiliate Partner for Diabetes Care Program
The Blue Cross Blue Shield Association has announced a partnership with a Google-affiliated company to provide personalized type 2 diabetes care to members of its health plans.
Many With Ovarian Cancer Choose Maintenance Therapy to Buy Time for Survival
A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.
Liver Debulking for Pancreatic Neuroendocrine Tumors May Be Effective at 70%
Debulking metastases of pancreatic neuroendocrine tumors may be effective at a threshold of greater than or equal to 70%, indicating that liver debulking criteria could possibly be extend to this threshold.
Nonadherence to Second-Line Therapy Reduces PFS in Renal Cell Carcinoma
A recent study examined the effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.
Gemcitabine Lowers Recurrence Rate in Nonmuscle Invasive Bladder Cancer
Intravesical installation with gemcitabine following transurethral resection of bladder tumor is associated with a reduced recurrence rate of nonmuscle invasive bladder cancer in patients with low-grade disease.
Adding Daratumumab to Common Multiple Myeloma Treatment Combo Improves PFS
A recent comparative study examined whether chemotherapy alone is as effective as adjuvant radiotherapy plus chemotherapy in patients with high-risk grade 2 glioma.
Many Patients With CLL Prefer Shorter PFS Over Serious Adverse Events
A recent study found that patients with CLL value higher progression-free survival as an outcome of therapy, but would accept significant reductions in PFS to avoid serious adverse events.
Chemotherapy Plus RT vs Chemotherapy Alone in Bladder Cancer
In patients with locally advanced bladder cancer, the use of adjuvant chemotherapy plus sequential radiotherapy is associated with significant improvements in locoregional recurrence-free survival and modest improvements in disease-free survival compared with chemotherapy alone.
Novel Clinical-Genomic Risk Group Classification Validated in Prostate Cancer
A new clinical-genomic risk group classification may accurately identify patients at low, intermediate, and high risk for metastasis in localized prostate cancer.
Despite Lack of Evidence, Clinicians Still Use Aggressive Breast Cancer Therapy
Many oncologists still use adjuvant radiotherapy following lumpectomy in older women with stage I estrogen receptor-positive breast cancer, despite the lack of evidence for survival advantage.
